scholarly journals Synergistic effect of doxycycline and fluconazole againstCandida albicansbiofilms and the impact of calcium channel blockers

2013 ◽  
Vol 13 (5) ◽  
pp. 453-462 ◽  
Author(s):  
Yuan Gao ◽  
Caiqing Zhang ◽  
Chunyan Lu ◽  
Ping Liu ◽  
Yan Li ◽  
...  
Keyword(s):  
Synergistic Effect ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers ◽  
The Impact

scholarly journals Impact of antihypertensive therapy on the functional state of the pituitary-gonadal system in patients with arterial hypertension

2005 ◽  
Vol 11 (1) ◽  
pp. 34-38 ◽  
Author(s):  
N. V. Ivanov
Keyword(s):  
Arterial Hypertension ◽  
Calcium Channel ◽  
Antihypertensive Therapy ◽  
Calcium Channel Blockers ◽  
Ace Inhibitors ◽  
Antihypertensive Agents ◽  
Free Testosterone ◽  
Blood Levels ◽  
Channel Blockers ◽  
The Impact

The aim of the study was to evaluate the impact of antihypertensive therapy with slow calcium-channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and ß-adrenergic receptor blockers on the metabolism and blood levels of major adrenal androgens and gonads, as well as the insulin resistance in males with arterial hypertension (AH) Ninety-one patients with AH and 15 age-matched healthy male controls were examined The hypertensive males treated with slow calcium-channel blockers or ACE inhibitors were found to have a lower level of insulin and higher levels of dehydroepiandrosterone sulfate and free testosterone on the 30th day of treatment Those on blockers were observed to have a higher level of insulin and lower levels of major adrenal and testicular androgens as compared with their baseline levels Therapy did not alter the levels of gonadotropic hormones, estradiol, and cortisol and they did not differ in the compared groups The family history of AH has a modulating effect on a hormonal response in males with AH treated with antihypertensive agents

scholarly journals The impact of hypertension and use of calcium channel blockers on tuberculosis treatment outcomes

2020 ◽  
Author(s):  
Vignesh Chidambaram ◽  
Akshay Gupte ◽  
Jann-Yuan Wang ◽  
Jonathan Golub ◽  
Petros Karakousis
Keyword(s):  
Calcium Channel ◽  
Treatment Outcomes ◽  
Calcium Channel Blockers ◽  
Cox Regression ◽  
Multivariable Analysis ◽  
Channel Blockers ◽  
Tb Treatment ◽  
All Cause Mortality ◽  
The Impact ◽  
Related Mortality

Background: Hypertension induces systemic inflammation, but its impact on the outcome of infectious diseases like tuberculosis (TB) is unknown. Calcium channel blockers (CCB) improve TB treatment outcomes in pre-clinical models, but their effect in patients with TB remain unclear. Methods: This retrospective cohort study, including all patients > 18 years receiving treatment for culture-confirmed, drug-sensitive TB from 2000 to 2016 at the National Taiwan University Hospital, assessed the association of hypertension and CCB use with all-cause and infection-related mortality during the first 9 months of TB treatment, as well as sputum-smear microscopy and sputum-culture positivity at 2 and 6 months. Results: 1052 of the 2894 patients (36.4%) had hypertension. Multivariable analysis revealed that hypertension was associated with increased mortality due to all causes (HR 1.57, 95% confidence interval[CI], 1.23-1.99) and infections (HR 1.87, 95%CI, 1.34-2.6), but there was no statistical difference in microbiological outcomes when stratified based on hypertensive group. Dihydropyridine-CCB (DHP-CCB) use was associated with reduced all-cause mortality (HR 0.67, 95%CI: 0.45-0.98) only by univariate Cox regression. There was no association between DHP-CCB use and infection-related mortality (HR 0.78, 95%CI: 0.46-1.34) or microbiological outcomes in univariate or multivariate regression analyses. Conclusions: Patients with hypertension have increased all-cause mortality and infection-related mortality during the 9 months following TB treatment initiation. DHP-CCB use may lower all-cause mortality in TB patients with hypertension. The presence of hypertension or the use of CCB did not result in a significant change in microbiological outcomes. Keywords: Tuberculosis, hypertension, calcium channel blockers, mortality, treatment outcomes

Beta-blocker and calcium-channel blocker therapy in patients with cardiovascular pathologies during post-COVID period

2021 ◽  
Author(s):  
А.Г. Арутюнов ◽  
Г.П. Арутюнов ◽  
Е.И. Тарловская ◽  
Т.И. Батлук ◽  
Р.А. Башкинов ◽  
...  
Keyword(s):  
Calcium Channel ◽  
Beta Blocker ◽  
Calcium Channel Blockers ◽  
Large Scale ◽  
Channel Blockers ◽  
Blocker Therapy ◽  
Cardiovascular Patients ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
The Impact

С начала 2020 г. в мире распространилась инфекция, вызванная вирусом SARS-CoV-2, что в дальнейшем привело к пандемии COVID-19. Долгое время вопросы ведения пациентов с новой коронавирусной инфекцией в остром периоде рассматривались как первоочередные. По мере накопления клинического опыта и данных о возбудителе новой коронавирусной инфекции стало очевидно, что проблема последствий перенесенного COVID-19 и ведения пациентов на постгоспитальном этапе является такой же важной. В силу прямой и опосредованной кардиотоксичности вируса SARS-CoV-2 особую группу риска на всех этапах составляют пациенты с сердечно-сосудистыми заболеваниями. Поэтому одной из важных задач мирового медицинского сообщества стала разработка способов улучшения качества и прогноза жизни пациентов с сердечно-сосудистыми заболеваниями в постковидном периоде. В статье сделан обзор наиболее крупных исследований, включая данные регистра «Анализ динамики коморбидных заболеваний пациентов, перенесших инфицирование SARS-CoV-2 (AКТИВ SARS-CoV-2)», по вопросу медикаментозной терапии пациентов с сердечно-сосудистыми заболеваниями с акцентом на бета-адреноблокаторы и блокаторы кальциевых каналов. В представленных работах терапия бета-адреноблокаторами продемонстрировала благоприятное влияние на тяжесть течения новой коронавирусной инфекции у пациентов с сердечно-сосудистыми заболеваниями, снижение смертности на госпитальном и в отдаленном постгоспитальном периодах. Данные по применению блокаторов кальциевых каналов изучены в меньшей степени, но можно отметить, что данная группа препаратов является одной из самых часто назначаемых в терапии пациентов с сохранением стойких жалоб на повышение артериального давления на постгоспитальном этапе. Требуется дальнейшее изучение влияния отдельных классов антигипертензивных препаратов на прогноз пациентов с сердечно-сосудистыми заболеваниями и COVID-19. Early in 2020, the infection caused by SARS-CoV-2 emerged and caused the COVID-19 pandemic. For a long time, management of patients with the acute novel coronavirus infection was of primary importance. With accumulation of clinical information and data on the causative agents of novel coronavirus infection it became obvious that the COVID-19 consequences and post-hospital follow-up of patients are important as well. Due to the direct and mediated cardiac toxicity of SARS-CoV-2 virus, cardiovascular patients are at high risk at any stage of the disease. Therefore, one of the priorities for healthcare professionals is development of the ways to improve the quality and prognosis of life for cardiovascular patients in the post-COVID period. The article discusses large-scale studies including the data from the International Register «Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients» (AСTIV-SARS-CoV-2), as regards drug therapy of cardiovascular patients with a focus on beta-blockers and calcium-channel blockers. In mentioned publications, beta-blocker therapy demonstrated favourable impact on the novel coronavirus infection severity in cardiovascular patients, reduction in mortality rates during the hospital and post-hospital periods. Data on the use of calcium-channel blockers have been studied to a lesser extent; however, calcium-channel blockers are thought to be one of the most commonly prescribed groups in the therapy of patients with persistent complaints of high blood pressure at the post-hospital period. A study of the impact of some categories of antihypertensives on the outcome for cardiovascular patients with COVID-19 is warranted.

scholarly journals Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0150859 ◽  
Author(s):  
Shuyuan Liu ◽  
Longtao Yue ◽  
Wenrui Gu ◽  
Xiuyun Li ◽  
Liuping Zhang ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Synergistic Effect ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers

scholarly journals Renin–Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study

2020 ◽  
Vol 9 (19) ◽  
Author(s):  
Christian Fynbo Christiansen ◽  
Uffe Heide‐Jørgensen ◽  
Thomas Bøjer Rasmussen ◽  
Jacob Bodilsen ◽  
Ole Schmeltz Søgaard ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Cohort Study ◽  
Intensive Care ◽  
Propensity Score ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Angiotensin Receptor Blockers ◽  
Channel Blockers ◽  
Increased Risk ◽  
The Impact

Background Angiotensin‐converting enzyme inhibitors (ACE‐Is) and angiotensin receptor blockers (ARBs) may worsen the prognosis of coronavirus disease 2019, but any association could be confounded by the cardiometabolic conditions indicating ACE‐I/ARB use. We therefore examined the impact of ACE‐Is/ARBs on respiratory tract infection outcomes. Methods and Results This cohort study included all adult patients hospitalized with influenza or pneumonia from 2005 to 2018 in Denmark using population‐based medical databases. Thirty‐day mortality and risk of admission to the intensive care unit in ACE‐Is/ARBs users was compared with nonusers and with users of calcium channel blockers. We used propensity scores to handle confounding and computed propensity score‐weighted risks, risk differences (RDs), and risk ratios (RRs). Of 568 019 patients hospitalized with influenza or pneumonia, 100 278 were ACE‐I/ARB users and 37 961 were users of calcium channel blockers. In propensity score‐weighted analyses, ACE‐I/ARB users had marginally lower 30‐day mortality than users of calcium channel blockers (13.9% versus 14.5%; RD, −0.6%; 95% CI, −1.0 to −0.1; RR, 0.96; 95% CI, 0.93–0.99), and a lower risk of admission to the intensive care unit (8.0% versus 9.6%; RD, −1.6%; 95% CI, −2.0 to −1.2; RR, 0.83; 95% CI, 0.80–0.87). Compared with nonusers, current ACE‐I/ARB users had lower mortality (RD, −2.4%; 95% CI, −2.8 to −2.0; RR, 0.85; 95% CI, 0.83–0.87), but similar risk of admission to the intensive care unit (RD, 0.4%; 95% CI, 0.0–0.7; RR, 1.04; 95% CI, 1.00–1.09). Conclusions Among patients with influenza or pneumonia, ACE‐I/ARB users had no increased risk of admission to the intensive care unit and slightly reduced mortality after controlling for confounding.

scholarly journals The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes

2020 ◽  
Author(s):  
Vignesh Chidambaram ◽  
Akshay Gupte ◽  
Jann-Yuan Wang ◽  
Jonathan E Golub ◽  
Petros C Karakousis
Keyword(s):  
Calcium Channel ◽  
Treatment Outcomes ◽  
Calcium Channel Blockers ◽  
Cox Regression ◽  
Multivariable Analysis ◽  
Channel Blockers ◽  
Tb Treatment ◽  
All Cause Mortality ◽  
The Impact ◽  
Related Mortality

Abstract Background Hypertension induces systemic inflammation, but its impact on the outcome of infectious diseases like tuberculosis (TB) is unknown. Calcium channel blockers (CCB) improve TB treatment outcomes in pre-clinical models, but their effect in patients with TB remain unclear. Methods This retrospective cohort study, including all patients > 18 years receiving treatment for culture-confirmed, drug-sensitive TB from 2000 to 2016 at the National Taiwan University Hospital, assessed the association of hypertension and CCB use with all-cause and infection-related mortality during the first 9 months of TB treatment, as well as sputum-smear microscopy and sputum-culture positivity at 2 and 6 months. Results 1052 of the 2894 patients (36.4%) had hypertension. Multivariable analysis revealed that hypertension was associated with increased mortality due to all causes (HR 1.57, 95% confidence interval[CI], 1.23-1.99) and infections (HR 1.87, 95%CI, 1.34-2.6), but there was no statistical difference in microbiological outcomes when stratified based on hypertensive group. Dihydropyridine-CCB (DHP-CCB) use was associated with reduced all-cause mortality (HR 0.67, 95%CI: 0.45-0.98) only by univariate Cox regression. There was no association between DHP-CCB use and infection-related mortality (HR 0.78, 95%CI: 0.46-1.34) or microbiological outcomes in univariate or multivariate regression analyses. Conclusions Patients with hypertension have increased all-cause mortality and infection-related mortality during the 9 months following TB treatment initiation. DHP-CCB use may lower all-cause mortality in TB patients with hypertension. The presence of hypertension or the use of CCB did not result in a significant change in microbiological outcomes.

scholarly journals Opiate analgesics as possible mechanisms for direct regulation of human oxytocin-induced uterine activity tested on labor model in experiment with isolated strips of myometrium

2015 ◽  
Vol 64 (6) ◽  
pp. 31-37
Author(s):  
Andrey Gennadyevich Kiselev ◽  
Alexey Gennadyevich Savitsky ◽  
Ekaterina Sergeevna Orlova
Keyword(s):  
Synergistic Effect ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Contractile Activity ◽  
Channel Blockers ◽  
Experimental Conditions ◽  
Uterine Activity ◽  
Opiate Analgesics ◽  
Direct Regulation

In this experiment on 38 isolated strips of myometrium (under the experimental conditions in vitro) we have demonstrated the possibility to assess the nature of myometrium contractions as a model of labor. We have recorded contractions caused by pre-stretching bands as well as contractions induced by oxytocin. We have identified the changes in the rhythm and amplitude of contractions in the background of opiates and calcium channel blockers, and demonstrated synergistic effect of opiates acts of on the contractile activity of the myometrium strips through calcium channels.

Sign in / Sign up

Export Citation Format

Share Document